Skip to content

Bicalutamide

FDA-approved product (tablet, oral), marketed as Bicalutamide, Casodex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Bicalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bicalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

    NCT00769795 · start 2008-10

    Registered record
    Registry ID
    NCT00769795
    Conditions
    Prostate Cancer
    Interventions
    IMC-A12; Bicalutamide; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-11
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionIMC-A12; Bicalutamide; Goserelin
    PhasePhase 2
    Registry statusCompleted
  • Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

    NCT00567580 · start 2008-02

    Registered record
    Registry ID
    NCT00567580
    Conditions
    Prostate Cancer
    Interventions
    PBRT; PLNRT; AA; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    1,792

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPBRT; PLNRT; AA; LHRH agonist
    PhasePhase 3
    Registry statusUnknown
  • RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

    NCT00630344 · start 2008-02

    Registered record
    Registry ID
    NCT00630344
    Conditions
    Prostate Cancer
    Interventions
    RAD001; Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2012-05
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRAD001; Bicalutamide
    PhasePhase 2
    Registry statusCompleted
  • Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

    NCT00589472 · start 2007-11

    Registered record
    Registry ID
    NCT00589472
    Conditions
    Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
    Interventions
    Bicalutamide; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate; Therapeutic Conventional Surgery; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-11
    Completion
    2010-06
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer +1 more
    InterventionBicalutamide; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate +2 more
    PhasePhase 2
    Registry statusCompleted
  • Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

    NCT00470834 · start 2007-05

    Registered record
    Registry ID
    NCT00470834
    Conditions
    Neoplasms, Prostate
    Interventions
    dutasteride; placebo; bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2013-02
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Prostate
    Interventiondutasteride; placebo; bicalutamide
    PhasePhase 4
    Registry statusCompleted
  • Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer

    NCT02175212 · start 2005-11

    Registered record
    Registry ID
    NCT02175212
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Short term androgen deprivation; Long term androgen deprivation; Short term androgen deprivation; Long term androgen deprivation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11
    Completion
    2020-09-24
    Enrolment
    362

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionShort term androgen deprivation; Long term androgen deprivation; Short term androgen deprivation; Long term androgen deprivation
    PhasePhase 3
    Registry statusCompleted
  • Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy

    NCT02382094 · start 2005-06

    Registered record
    Registry ID
    NCT02382094
    Conditions
    Prostate Cancer
    Interventions
    Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-06
    Completion
    2012-07
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBicalutamide
    PhasePhase 3
    Registry statusCompleted
  • External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

    NCT00388804 · start 2005-02

    Registered record
    Registry ID
    NCT00388804
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Bicalutamide; Leuprolide; Goserelin; Flutamide; Questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-02
    Completion
    2011-04
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Bicalutamide; Leuprolide; Goserelin +2 more
    PhasePhase 3
    Registry statusTerminated
  • Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

    NCT00482807 · start 2004-08-31

    Registered record
    Registry ID
    NCT00482807
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; docetaxel; goserelin; intensity-modulated radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-08-31
    Completion
    2010-03-09
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; docetaxel; goserelin; intensity-modulated radiation therapy
    PhasePhase 1
    Registry statusCompleted
  • Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

    NCT00170157 · start 2004-06

    Registered record
    Registry ID
    NCT00170157
    Conditions
    Prostate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    Bicalutamide; Flutamide; Goserelin Acetate; Ipilimumab; Leuprolide Acetate; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-06
    Completion
    2013-06
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer +1 more
    InterventionBicalutamide; Flutamide; Goserelin Acetate; Ipilimumab +2 more
    PhasePhase 2
    Registry statusCompleted
  • Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX

    NCT00590213 · start 2003-06

    Registered record
    Registry ID
    NCT00590213
    Conditions
    Prostate Cancer
    Interventions
    Casodex 150mg; Radiotherapy; Haematology
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-06
    Completion
    Not recorded
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCasodex 150mg; Radiotherapy; Haematology
    PhasePhase 4
    Registry statusCompleted
  • Casodex - Nolvadex Combination

    NCT00637871 · start 2002-11

    Registered record
    Registry ID
    NCT00637871
    Conditions
    Gynaecomastia; Prostate Cancer
    Interventions
    Casodex; Tamoxifen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-11
    Completion
    2005-08
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGynaecomastia; Prostate Cancer
    InterventionCasodex; Tamoxifen
    PhasePhase 2
    Registry statusCompleted
  • Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy

    NCT00418080 · start 2002-04

    Registered record
    Registry ID
    NCT00418080
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-04
    Completion
    2006-12
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide
    PhasePhase 2
    Registry statusCompleted
  • SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

    NCT00026377 · start 2001-11

    Registered record
    Registry ID
    NCT00026377
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; goserelin acetate; leuprolide acetate; SU5416; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-11
    Completion
    2003-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; goserelin acetate; leuprolide acetate +2 more
    PhasePhase 1
    Registry statusCompleted
  • Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

    NCT00586898 · start 2001-07

    Registered record
    Registry ID
    NCT00586898
    Conditions
    Prostate; Cancer; Hormonal Cycling
    Interventions
    GnRH; Ketoconazole; Bicalutamide; Testosterone transdermal gel; Estrogen transdermal patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate; Cancer; Hormonal Cycling
    InterventionGnRH; Ketoconazole; Bicalutamide; Testosterone transdermal gel +1 more
    PhasePhase 2
    Registry statusCompleted